You are here: Industry Insights > Market News > Zydus receives final approval from the USFDA for Methotrexate Tablets USP

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Zydus receives final approval from the USFDA for Methotrexate Tablets USP

firstwordpharmaJanuary 19, 2017

Tag: approval , head and neck cancers

Favorites

Zydus Cadila has received the final approval from the USFDA to market Methotrexate Tablets USP, 2.5 mg, a chemotherapy drug used for leukemias, lymphomas, breast cancer, lung cancer, head and neck cancers and other cancers.

The drug will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 105 approvals and has so far filed nearly 275 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 19,500 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

Previous:Boehringer Ingelheim biosimilar candidate to Humira accepted for EMA and FDA regulatory review

Next:Allergan, Gedeon’s fibroid drug hits PhIII targets

Zydus receives final approval from the USFDA for Methotrexate Tablets USP

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may like
More>>

Zydus receives final approval from the USFDA for Methotrexate Tablets USP

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may likeMore>>

You may like
More>>